CHPI’s 2017 Access to Innovative Medicines (AIM) series.
The Patented Medicine Prices Review Board (PMRPB) is the federal government agency that regulates the prices of patented medicines in Canada. The federal government has proposed amendments to the regulations and guidelines governing the PMPRB. The primary purpose of this paper is to critically examine the proposed regulatory changes. However, the process of re-evaluation initiated by the PMPRB presents a rare opportunity for policy-makers to reassess the relevancy of the PMPRB itself. Therefore, this paper offers an independent assessment of the PMPRB’s mandate and recommends alternative policy options.
